Advancements in gallium-based radiopharmaceuticals are transforming the landscape of oncologic diagnostics, with several agents already in routine clinical practice and more in development. Explore the techniques employed to produce the gallium-68 on both small and large scales to satisfy clinical and research needs.

In this infographic, the focus is on circulating biomarkers for neuroendocrine neoplasms, which are highly clinically relevant. Learn all about them.

Current functional imaging techniques in nuclear medicine, such as positron emission tomography (PET) and single photon emission computed tomography (SPECT), play an essential role in clinical oncology by aiding early diagnosis, predicting treatment responses, and monitoring the disease. Do you know the key differences between these two techniques?

Find out the difference between the production of carrier-added versus non-carrier-added lutetium-177, a radioisotope of choice for targeted radiopharmaceutical therapy.

Most medical-grade radionuclides used in synthesizing diagnostic and therapeutic radiopharmaceuticals are produced through one of the four methods of nuclear activation: fission, neutron activation, cyclotron and generator systems. Find out more in the infographic.​

Discover the steps involved in a typical dosimetry workflow and compare the benefits and challenges of the dosimetry-based approach to targeted radiopharmaceutical therapy with a one-size-fits-all approach.​

Learn more about targeted radiopharmaceutical therapy and the mechanism of action of radiotherapeutic agents used for the treatment of tumors expressing specific receptors on their surface.

Highly precise radiopharmaceuticals can be used to effectively diagnose or treat tumors expressing specific receptors on their surface. Watch the video to learn more about their mode of action (MoA).